About Amber Therapeutics

Amber Therapeutics develops the first adaptive neuromodulation therapy capable of treating mixed urinary incontinence, affecting 40 million women in the US. The fully implantable Picostim System targets the pudendal nerve with a device that both stimulates and senses physiological responses, adapting dynamically between operation modes. The therapy addresses both urge and stress incontinence simultaneously, where existing therapies treat only one type. Early human trials demonstrate strong pilot efficacy and clinically significant improvements in quality of life. The company combines deep medical device expertise with transformational innovation, restoring normal physiological function for women with this debilitating condition.